Evolus, Inc. (EOLS)

Market Cap	359.78M -61.1%
Revenue (ttm)	297.18M +11.6%
Net Income	-51.64M
EPS	-0.80
Shares Out	65.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,726,764
Open	5.68
Previous Close	5.66
Day's Range	5.17 - 5.68
52-Week Range	4.09 - 14.28
Beta	1.01
Analysts	Strong Buy
Price Target	15.50 (+180.29%)
Earnings Date	Mar 3, 2026

About EOLS

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newpo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 8, 2018
• Employees: 334
• Stock Exchange: NASDAQ
• Ticker Symbol: EOLS
• Website: https://www.evolus.com

Financial Performance

In 2025, Evolus's revenue was $297.18 million, an increase of 11.61% compared to the previous year's $266.27 million. Losses were -$51.64 million, 2.42% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for EOLS stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 180.29% from the latest price.

Price Target

$15.5

(180.29% upside)

Analyst Consensus: Strong Buy